Everything below concerns albumin binding. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-14. Numbers and descriptions here follow the published literature rather than marketing material.
定量分析的主流方法是反相高效液相色谱联用紫外或质谱检测，利用肽在疏水固定相上的保留行为确定纯度与含量。对于生物基质中的浓度测定，常采用液相色谱串联质谱，并配合固相萃取或蛋白沉淀进行样品前处理。免疫分析法也可使用，但可能受到结构相关肽的交叉反应干扰。
纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息：前者反映疏水性杂质，后者反映聚集体，质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异，属于需要逐案验证的问题。
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
| Property | Value | Notes |
|---|---|---|
| 储存温度 | 2 至 8 摄氏度 | 固体粉末，避光密封 |
| 外观 | 白色至类白色冻干粉 | 溶解后为澄清至微乳光 |
| 溶解性 | 易溶于水性缓冲液 | 避免剧烈振荡 |
| 常规纯度方法 | 反相高效液相色谱 | 紫外或质谱检测 |
| 定量方法 | 液相色谱串联质谱 | 配合固相萃取前处理 |
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Chair of Trustees, Molly Rose Foundation. For services to Child Safety Online. Martin Henry Charles Russell, DL. For services to the community in the London Borough of Barnet. Rosemary Priscilla Irene Russell. Art and Design and Technology Technician, The Ursuline Academy Ilford. For services to Education and to Diversity in STEM. Elizabeth Joan Ryan. Lately Volunteer, Luton, South Bedfordshire and Harpenden Samaritans. For services to Suicide Prevention. Sadia Sadiq. Manager, Community Care and Wellbeing Services. For services to Minority Ethnic Communities in Wales. Lorraine Sanda. Strategic Director of People, Clackmannanshire Council. For services to Children and Families. Carolene Euleata Sargeant (Carolene Hinds). Independent Performing Arts Professional. For services to Dance. Professor William Peter Saunders. Chief Creative Officer, StoryFutures at Royal Holloway University. For services to the Creative Industries. Alison Melanie Savage. Officer Commanding, The Services Cotswold Centre. For services to Military Families. Jacqueline Savage. Volunteer. For services to Social Care. Majida Aly Sayam. Founder and Director, Jannaty Women's Social Society. For charitable services to Ethnic Minority Women. Kimberley Louise Scott. Lately Assistant Director of Education, Education Authority. For services to Education. Jacqueline Scrivens (Jacqueline Forester). Proprietor, The Woodshed Forest School Nursery. For services to Early Years Child-Lead Learning. Josephine Patricia Segal. Co-Founder, Spread a Smile.
Under CLIA, anyone, including patients and their families, laboratory personnel, and the general public, can submit anonymous complaints if there are concerns about the quality of laboratory testing. The most common CLIA complaints are concerns about a laboratory's operations, such as: unlabeled specimens, unqualified staff, record falsification, missing or incorrect test results and the confidentiality of patient information. For laboratories accredited by a laboratory Accreditation Organization (AO), complaints may be referred to the laboratory's AO. Though anyone may lodge a complaint, relatively few laboratory complaints have been filed. This may be due to a lack of publicity about complaint filing, since CLIA does not require that laboratory employees or patients be made aware of how to file a complaint, and to privacy concerns stemming from the lack of whistleblower protections. Other limiting factors include an increasing reliance on on-the-job (OTJ)- trained lab personnel who are unaware of regulatory requirements, foreign-sponsored H1b medical technologists fearing retaliatory deportation, and an aging workforce awaiting retirement. Laboratory whistleblowers may face countermeasures such as cover-ups, loss of income, position, or employment, punitive lawsuits, and attacks on their reputation, which would degrade their living conditions and dissuade them from bringing fraud to light. A June 2006 GAO report found that lab workers may file complaints infrequently due to concerns about retaliation and a lack of understanding of how to do so.
As described above, the use of N-terminal and side chain protecting groups is essential during peptide synthesis to avoid undesirable side reactions, such as self-coupling of the activated amino acid leading to (polymerization). This would compete with the intended peptide coupling reaction, resulting in low yield or even complete failure to synthesize the desired peptide. Two principle protecting group schemes are typically used in solid phase peptide synthesis: so-called Boc/benzyl and Fmoc/tert-butyl approaches. The Boc/Bzl strategy utilizes TFA-labile N-terminal Boc protection alongside side chain protection that is removed using anhydrous hydrogen fluoride during the final cleavage step (with simultaneous cleavage of the peptide from the solid support). Fmoc/tBu SPPS uses base-labile Fmoc N-terminal protection, with side chain protection and a resin linkage that are acid-labile (final acidic cleavage is carried out via TFA treatment). Both approaches, including the advantages and disadvantages of each, are outlined in more detail below.
Sources: en.wikipedia.org
Considering the likely abundance ratio of 244Pu to 238U in the early solar system (~0.008), this upper limit is still 18 times greater than the expected present 244Pu content in the bastnasite sample (1.2×10−21 g/g). Live interstellar plutonium-244 has been detected in meteorite dust in marine sediments, though the levels detected are much lower than would be expected from current modelling of the in-fall from the interstellar medium. Trace amounts of 244Pu were also found in rock from the Pacific ocean by a Japanese oil exploration company. It is important to recall, however, that in order to be a primordial nuclide – one whose origin lay in the amalgam orbiting the Sun that ultimately coalesced into the Earth – the plutonium-244 must have comprised some of the solar nebula, rather than having been replenished by extrasolar meteoritic dust.
=== Differences from deepfakes === Although AI-generated pornography and deepfake pornography rely on similar generative AI technologies, deepfakes involve altering existing content, usually photographs of unconsenting individuals, while AI-generated pornography usually synthesizes explicit content from scratch without using people's likenesses directly. Digital image analysis expert Hany Farid opined that, while deepfake pornography of unconsenting individuals should be illegal, the legal status of AI-generated pornography created from scratch is "more complex".
=== Monotreme research === Flannery et al. (2026) review the fossil record and evolutionary history of monotremes. Chimento (2026) reports evidence of similarities of morphology of teeth and mandibles of monotremes, meridiolestidans and dryolestoids from Northern Hemisphere, and interprets the available data as consistent with origin of monotreme dental pattern from teeth of Gondwanan dryolestoids. Ziegler & Lockett (2026) report the discovery of a skull of Megalibgwilia owenii from the Foul Air Cave in the Buchan Caves Reserve, representing the first record of the species from Victoria (Australia).
This difference is reflected in their metabolism; M1 macrophages have the unique ability to metabolize arginine to the "killer" molecule nitric oxide, whereas M2 macrophages have the unique ability to metabolize arginine to the "repair" molecule ornithine. However, this dichotomy has been recently questioned as further complexity has been discovered. Macrophages are widely thought of as highly plastic and fluid cells, with a fluctuating phenotype. Human macrophages are about 21 micrometres (0.00083 in) in diameter and are produced by the differentiation of monocytes in tissues. They can be identified using flow cytometry or immunohistochemical staining by their specific expression of proteins such as CD14, CD40, CD11b, CD64, F4/80 (mice)/EMR1 (human), lysozyme M, MAC-1/MAC-3 and CD68. Macrophages were first discovered and named by Élie Metchnikoff, a Russian Empire zoologist, in 1884.
Sources: en.wikipedia.org
建议在低温、避光、干燥环境中密封保存，常见条件为 2 至 8 摄氏度，长期存放可置于更低温度。应避免反复冻融，并尽量减少容器开启次数。
溶解后的稳定时间通常短于固体形态，受浓度、缓冲液和容器材质影响。冷藏条件下一般只能维持较短时间，具体期限应通过实际稳定性实验确认。
反相高效液相色谱用于纯度与含量测定，液相色谱串联质谱用于生物基质中的定量，体积排阻色谱用于检测聚集体。多种方法结合才能较完整地表征样品。
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.